Expanded Recommendations for Use of Pneumococcal Conjugate Vaccines Among Adults Aged ≥50 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, 2024.

• Tác giả: Emma Accorsi, Adam L Cohen, Ryan Gierke, Mini Kamboj, Miwako Kobayashi, George A Kuchel, Andrew J Leidner, Jamie Loehr, Pedro Moro, Robert Schechter, Wei Xing
• Ngôn ngữ: eng
• Ký hiệu phân loại: 787.84 *Mandolins
• Thông tin xuất bản: United States : MMWR. Morbidity and mortality weekly report , 2025
• Bộ sưu tập: NCBI
• ID: 678613

Tóm tắt

 Before October 2024, the Advisory Committee on Immunization Practices (ACIP) recommended use of a pneumococcal conjugate vaccine (PCV) for all adults aged ≥65 years, as well as for those aged 19-64 years with risk conditions for pneumococcal disease who have not received a PCV or whose vaccination history is unknown. Options included either 20-valent PCV (PCV20
  Prevnar20
  Wyeth Pharmaceuticals) or 21-valent PCV (PCV21
  CAPVAXIVE
  Merck Sharp & Dohme) alone or 15-valent PCV (PCV15
  VAXNEUVANCE
  Merck Sharp & Dohme) in series with 23-valent pneumococcal polysaccharide vaccine (PPSV23
  Pneumovax23
  Merck Sharp & Dohme). There are additional recommendations for use of PCV20 or PCV21 for adults who started their pneumococcal vaccination series with 13-valent PCV (PCV13
  Prevnar13
  Wyeth Pharmaceuticals). The ACIP Pneumococcal Vaccines Work Group employed the Evidence to Recommendations framework to guide its deliberations on expanding the age-based PCV recommendation to include adults aged 50-64 years. On October 23, 2024, ACIP recommended a single dose of PCV for all PCV-naïve adults aged ≥50 years. Recommendations for PCVs among adults aged 19-49 years with risk conditions and PCV13-vaccinated adults have not changed from previous recommendations. This report summarizes evidence considered for these recommendations and provides updated clinical guidance for use of PCV.